Notes

1 - Summary XNAS
NAME Repro Med Systems XNYS
http://www.nasdaq.com/symbol/krmd Ticket KRMD PINX
Exchange NASDAQ-CM
http://financials.morningstar.com/company-profile/c.action?t=krmd Stock type Speculative Growth
2 Morning star rating -
Business Description Sector Healthcare http://investors.morningstar.com/ownership/shareholders-buying.html?t=krmd
Industry Medical Instruments & Supplies http://investors.morningstar.com/ownership/shareholders-selling.html?t=krmd
Stock Style Small Growth http://finance.yahoo.com/q/ks?s=krmd
Operation Details Employees 71 http://insiders.morningstar.com/trading/insider-activity.action?t=krmd
2 - Basic stuff (For comparing)
3 Community Rating - Current price 11
3 1 Year target -
1 50 Day Avg. Daily Volume 483450 http://www.nasdaq.com/symbol/krmd/stock-report *** PER SHARE ***
http://www.nasdaq.com/symbol/krmd Market Cap 437347941 Date 12 m EPS Dividend P/E Ratio
P/E Ratio N/A
3 Forward P/E 1 Yr. N/A
Earnings Per Share(EPS) N/A
Annualized Dividend N/A
Ex Dividend Date N/A
Dividend Pay Date N/A
Current Yield N/A
Key stats Price/Earnings TTM
https://www.morningstar.com/stocks/XNAS/krmd/quote.html Price/Book 38.92
Price/Sales TTM 18.58
Rev Growth (3 Yr Avg) 18.06
Net Income Growth (3 Yr Avg) -8.17
Operating Margin % TTM 17.28
Net Margin % TTM 2.44
ROA TTM 4.62
ROE TTM 5.59 http://www.nasdaq.com/symbol/krmd/analyst-research Earnings Growth to industry
Debt/Equity 0.02 P/E Ratio to industry


3 - Forecast
http://www.nasdaq.com/symbol/krmd/risk Risk (Max 500)
https://uk.finance.yahoo.com/q/ao?s=krmd Mean Recommendation (this week):
Median Target:
No. of Brokers:
http://community.nasdaq.com/community-ratings.aspx?stockticker=krmd Consensus
http://www.nasdaq.com/symbol/krmd/recommendations Analyst recommend
http://www.nasdaq.com/symbol/krmd/guru-analysis Peter Lynch
Benjamin Graham (Value)
https://www.morningstar.com/stocks/XNAS/krmd/quote.html Growth
Profitability
Morningstar Credit Rating*
4 - Detail stuff
http://financials.morningstar.com/income-statement/is.html?t=krmd Fiscal year ends in December. USD in millions except per share data. 2015-02 2016-02 2017-02 2018-12 2019-12 2011-12 2012-12 2013-12 2014-12 2015-12
Million Revenue 11 12 12 17 23
Export Cost of revenue 5 5 5 7 8
Gross profit 7 8 8 11 15
Operating expenses
Research and development 0 0 0 0 1
Sales, General and administrative 5 6 8 9 10
Other operating expenses 0 0 0 0 0
Total operating expenses 6 6 8 10 11
Operating income 1 1 -1 1 4
Interest Expense 0 0 0
Other income (expense) 0 0 0 0 -3 Earnings per share
Income before taxes 1 1 -1 1 1 Diluted
Provision for income taxes 0 0 0 0 0 EBITDA
Net income from continuing operations 1 1 -1 1 1





https://finance.yahoo.com/quote/krmd/key-statistics?ltr=1
Valuation Measures Enterprise Value (Jun 22, 2016)3: 55.87M
Trailing P/E (ttm, intraday): 80
Forward P/E (fye Dec 31,17)1: -
PEG Ratio (5 yr expected)1: -
Enterprise Value/Revenue (ttm)3: 11.23
Enterprise Value/EBITDA (ttm)6: -1.78k
Management Effectiveness Return on Equity (ttm): 5.59%
Income Statement Revenue (ttm): 23.16M
Revenue Per Share (ttm): 0.6
Qtrly Revenue Growth (yoy): 45.70%
Qtrly Earnings Growth (yoy): -%
Balance Sheet Total Cash (mrq): 5.87M
Total Cash Per Share (mrq): 0.15
Total Debt (mrq): 381.68k
Total Debt/Equity (mrq): 3.4
Current Ratio (mrq): 4.94
Book Value Per Share (mrq): N/A
Cash Flow Statement Operating Cash Flow (ttm): 320.62k
Levered Free Cash Flow (ttm): 2.07M
Stock Price History 52-Week Change3: 588.75%
S&P500 52-Week Change3: -0.38%
52-Week High (Nov 5, 2015)3: 12.84
52-Week Low (Feb 9, 2016)3: 1.52
50-Day Moving Average3: 9.12
200-Day Moving Average3: 6.67
Share Statistics % Held by Insiders1: 16.06%
% Held by Institutions1: 56.55%






http://financials.morningstar.com/ratios/r.html?t=krmd
Margins % of Sales 2010-02 2011-02 2012-02 2013-02 2014-02 2015-02 2016-02 2017-02 2018-12 2019-12 TTM
Revenue 100 100 100 100 100 100 100 100 100 100
COGS 33.47 33.68 35.23 36.31 38.96 40.53 37.92 38.43 37.71 35.87
Gross Margin 66.53 66.32 64.77 63.69 61.04 59.47 62.08 61.57 62.29 64.13
SG&A 44.96 39.98 41.56 45.65 44.27 42.58 48.52 63.18 52.41 42.19
R&D 0.74 0.72 1.41 1.9 2.51 4.16 1.69 1.93 1.39 3.2
Other 1.72 1.34 1.63 2.46 2.68 2.52 2.22 2.45 1.78 1.47
Operating Margin 19.11 24.28 20.17 13.68 11.58 10.2 9.65 -5.99 6.71 17.28
Net Int Inc & Other -1.56 -0.03 -0.12 -0.31 0.03 -0.65 -0.32 -0.33 0.07 -14.27
EBT Margin 17.55 24.25 20.05 13.37 11.62 9.56 9.33 -6.32 6.78 3.01


Profitability 2010-02 2011-02 2012-02 2013-02 2014-02 2015-02 2016-02 2017-02 2018-12 2019-12 TTM
Tax Rate % — 40.99 36.32 30.09 30.38 29.91 31.48 — 22.63 18.96
Net Margin % 23.35 14.31 12.77 9.35 8.09 6.7 6.39 -4.35 5.25 2.44
Asset Turnover (Average) 1.43 1.53 1.55 1.49 1.47 1.67 1.56 1.48 1.75 1.9
Return on Assets % 33.27 21.93 19.8 13.96 11.92 11.17 9.99 -6.46 9.19 4.62
Financial Leverage (Average) 1.77 1.38 1.35 1.28 1.2 1.16 1.18 1.22 1.18 1.24
Return on Equity % 73.64 33.78 27.06 18.36 14.73 13.14 11.69 -7.76 10.95 5.59
Return on Invested Capital % 46.88 26.83 25.24 17.72 14.69 13.07 11.82 -7.77 10.69 5.38
Interest Coverage 14.95 33.79 41.62 37.71 223.22 — 335.87 -410.82 — —
Growth 2010-02 2011-02 2012-02 2013-02 2014-02 2015-02 2016-02 2017-02 2018-12 2019-12 Latest Qtr
Revenue %
Year over Year — 30.35 29.87 21.49 12.04 29.27 8.92 0.38 20.63 33.47
3-Year Average — 27.98 22.94 27.17 20.91 20.73 16.41 12.22 11.96 18.06
5-Year Average — 23.03 29.8 27.02 20.39 24.4 20.01 13.98 14.76 18.25
10-Year Average — 8.96 13.77 16.7 18.99 21.84 21.51 21.63 20.26 19.23
Operating Income %
Year over Year — 65.6 7.89 -17.59 -5.15 13.87 2.96 — — 243.6
3-Year Average — 83.46 18.28 13.77 -5.52 -3.81 3.6 — 0.39 37.41
5-Year Average — — — 40.58 5.28 9.72 -0.23 — 1.58 26.63
10-Year Average — — — — — — — — 18 16.29
Net Income %
Year over Year — -20.84 15.88 -11.05 -3.08 7.06 3.95 — — -38.02
3-Year Average — — -7.5 -6.55 -0.03 -2.63 2.56 — 5.07 -8.17
5-Year Average — — — — -7.36 -3.27 2.14 — 3.96 -3.7
10-Year Average — — — — — — — — — -5.4
EPS %
Year over Year — — — — — — — — — -50
3-Year Average — — -12.64 — — — — — — -16.52
5-Year Average — — — — -7.79 — — — — -11.19
10-Year Average — — — — — — — — — -9.63


Cashflow Cash Flow Ratios 2010-02 2011-02 2012-02 2013-02 2014-02 2015-02 2016-02 2017-02 2018-12 2019-12 TTM
Operating Cash Flow Growth % YOY — 169.02 -45.49 39.99 21.61 -13.44 131.79 — — -78.33
Free Cash Flow Growth % YOY — 153.72 -60.8 -32.68 237.94 -88.85 — — — —
Health Balance Sheet Items (in %) 2010-02 2011-02 2012-02 2013-02 2014-02 2015-02 2016-02 2017-02 2018-12 2019-12 Latest Qtr
Cash & Short-Term Investments 27.22 42.93 36.57 39.11 40.04 38.69 53.17 43.76 49.85 42.29
Accounts Receivable 21.92 20.79 18.41 19.94 28.1 22.3 16.08 20.49 13.52 23.3
Inventory 21.24 19.45 24.3 20.57 13.19 16.85 12.39 16.57 19.95 17.21
Other Current Assets 12.58 4.62 9.24 3.23 3.96 3.31 3.16 2.15 2.34 2.79
Total Current Assets 82.97 87.79 88.52 82.85 85.29 81.14 84.8 82.98 85.66 85.59
Net PP&E 7.4 10.52 10.38 15.66 13.51 15.95 11.87 11.41 8.14 7.1
Intangibles 1.17 0.87 0.51 0.41 0.7 2.48 2.95 5.23 5.99 5.81
Other Long-Term Assets 8.46 0.82 0.59 1.08 0.5 0.43 0.37 0.39 0.2 1.5
Total Assets 100 100 100 100 100 100 100 100 100 100
Accounts Payable 2.7 4.6 4.15 1.97 3.97 3.34 3.67 9.45 4.3 4.13
Short-Term Debt 2.22 1.19 0.04 0.81 — — — — — —
Taxes Payable — — 2.04 2.27 2.68 — 1.54 — 0.16 1.47
Accrued Liabilities 8.49 2.69 3.2 3.93 5.42 5.85 7.72 7.27 10.53 10.71
Other Short-Term Liabilities 3.17 0.65 2.19 0.4 0.36 0.31 0.27 0.28 0.04 1.02
Total Current Liabilities 16.57 9.14 11.63 9.39 12.43 9.5 13.2 17 15.02 17.33
Long-Term Debt 20.88 14.06 0.03 7.04 — — — — — —
Other Long-Term Liabilities 6.02 4.58 14.44 5.66 3.95 4.34 2 1.28 — 1.73
Total Liabilities 43.47 27.78 26.11 22.1 16.38 13.84 15.2 18.29 15.02 19.06
Total Stockholders' Equity 56.53 72.22 73.89 77.9 83.62 86.16 84.8 81.71 84.98 80.94
Total Liabilities & Equity 100 100 100 100 100 100 100 100 100 100
Liquidity/Financial Health 2010-02 2011-02 2012-02 2013-02 2014-02 2015-02 2016-02 2017-02 2018-12 2019-12 Latest Qtr
Current Ratio 5.01 9.6 7.61 8.82 6.86 8.54 6.43 4.88 5.7 4.94
Quick Ratio 2.97 6.97 4.73 6.29 5.48 6.42 5.24 3.77 4.22 3.78
Financial Leverage 1.77 1.38 1.35 1.28 1.2 1.16 1.18 1.22 1.18 1.24
Debt/Equity 0.37 0.19 — 0.09 — — — — — 0.02

5 - Ownership
http://investors.morningstar.com/ownership/shareholders-overview.html?t=krmd
Owner Activity Individual Funds
Total Owners 54 29
New Owners 41 9
Sold Out 2 14
# of Owners Buying 6 7
# of Owners Selling 1 3
Total Shares Owned (Mil) 11 2
Total Shares Bought (Mil) 3 0
Total Shares Sold (Mil) 0 0
Fund Owners' Style Style # of Funds Shares Buy Sell Net % Chg
Large Value 2 88 1 -- --
Large Blend 16 889,669 11,433 3,626 0.89
Large Growth 1 16,832 8,343 -- --
Mid Value -- -- -- -- --
Mid Blend -- -- -- -- --
Mid Growth 1 36,000 -- -- --
Small Value -- -- -- -- --
Small Blend 1 3826 366 -- --
Small Growth 8 393490 18684 317 4.9
Total 29 1,339,905 38,827 3,943 2.67


6 - Key officers
http://insiders.morningstar.com/trading/key-executives.action?t=XNAS:krmd 1 - CEO Mr. Pettigrew has more than 23 years of sales and business development experience in the medical device industry, including the home infusion space. Prior to joining RMS (now KORU Medical Systems) as President and Chief Commercial Officer in 2018, Mr. Pettigrew held senior leadership positions at market-leading medical firms such as Moog, Inc. as Global Business Development and Group Director, Global Sales and Professional Services from 2011 through 2018, where he led commercialization and business development for the IV infusion and enteral feeding franchises in both the U.S. and international markets. Mr. Pettigrew also held management positions at Baxter (formerly Gambro) from 2008-2011, Boston Scientific from 1995-2008, and E&J Gallo from 1990-1995. Mr. Pettigrew earned his B.A. in Biology from the University of Colorado.
Board Member Since
11/28/2018
11/15/2018
11/14/2018
10/29/2018
10/29/2018

2 – CFO Karen Fisher has more than 25 years of financial experience in a variety of industries, most recently serving as the Assistant Controller for a global consumer products company. She has also held roles such as Chief Accounting Officer and Treasurer, and Controller. Ms. Fisher held multiple financial management roles covering financial analysis and reporting, budgeting, forecasting, acquisitions, and cash management. She is thoroughly knowledgeable in compliance with SEC regulation, GAAP, 10Q's, 10K's and Sarbanes-Oxley. Ms. Fisher is a Certified Public Accountant and a graduate of Arizona State University with a BS in Accounting.
Board Membership
11/15/2018
11/15/2018
11/15/2018
11/15/2018
11/15/2018

3 – COO Manny Marques has an engineering background in FDA Class II & III medical devices. He has a proven history of effectively transferring new products from R&D into manufacturing, while also reducing operating and manufacturing costs of existing products. Mr. Marques is a champion at enhancing operational management via implementation of Lean 6-Sigma Manufacturing techniques. Mr. Marques holds two U.S. patents for cardiovascular medical devices. Manny obtained a BS in Mechanical Engineering Technology and also an MS in Engineering Management from the New Jersey Institute of Technology.
Board Membership Date* Shares Transaction Value
11/15/2018
11/15/2018 07/01/2020 50,000 Exercise 23,000
11/15/2018 07/01/2020 125,000 Exercise 62,500
11/15/2018
08/15/2018

http://insiders.morningstar.com/trading/executive-compensation.action?t=krmd Age Total Calculated Compensation
Total Compensation 1-Year % Change
$3,781,176 105.91 %
krmdle - krmd 10k filling Compensation vs. Performance (1-Year % Change)
Committees CEO Compensation Stock Return Revenue Return on Equity Net Income
115.25% 295.76% 33.47% -44.98% -38.03%
http://insiders.morningstar.com/trading/executive-compensation.action?t=krmd 2011 2012 2013 2014 2015
Key Executive Compensation - - - 1836340 3781176
Donald B. Pettigrew/President and Chief Executive Officer - - - 836339 1800185
Daniel S. Goldberger/Former Chief Executive Officer and Executive Chairman of the Board - - - 727001 437962
Karen Fisher/Chief Financial Officer - - - 273000 897712
Manuel A. Marques/Chief Operating Officer - - - - 645317